| 24.09 08:11 | dpa-AFX: GSK: CHMP Issues Positive Opinion On New Fully Liquid Presentation Of Menveo Meningococcal Vaccine |
| 24.09 08:04 | dpa-AFX: *GSK SAYS MENVEO MENINGOCOCCAL VACCINE IN NEW SINGLE-VIAL, FULLY LIQUID PRESENTATION GETS POSITIVE EUROPEAN CHMP OPINION |
| 24.09 08:03 | dpa-AFX: *GSK'S MENVEO MENINGOCOCCAL VACCINE GETS POSITIVE EUROPEAN CHMP OPINION |
| 18.09 15:33 | dpa-AFX: GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines |
| 18.09 14:46 | dpa-AFX: *GSK REPORTS POSITIVE PHASE 3 TRIAL RESULTS FOR AREXVY CO-ADMINISTERED WITH SHINGRIX IN OLDER ADULTS |
| 18.09 14:42 | dpa-AFX: GSK Settles 2 Cases In California Against Zantac |
| 18.09 14:25 | dpa-AFX: *GSK CONFIRMS CONFIDENTIAL SETTLEMENTS IN CALIFORNIA BLADDER AND COLORECTAL CANCER CASES |
| 18.09 13:18 | dpa-AFX: ANALYSE-FLASH: Jefferies belässt GSK auf 'Buy' - Ziel 2100 Pence |
| 18.09 13:18 | dpa-AFX: Jefferies belässt GSK auf 'Buy' - Ziel 2100 Pence |
| 17.09 10:32 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt GSK auf 'Underweight' - Ziel 1550 Pence |
| 17.09 10:32 | dpa-AFX: JPMorgan belässt GSK auf 'Underweight' - Ziel 1550 Pence |
| 17.09 08:27 | dpa-AFX: GSK: Japan Accepts For Review NDA For Blenrep Combinations In Relapsed/refractory Multiple Myeloma |
| 17.09 08:10 | dpa-AFX: *GSK : BLENREP COMBINATIONS IN R/R MULTIPLE MYELOMA ACCEPTED FOR REGULATORY REVIEW IN JAPAN |
| 17.09 08:04 | dpa-AFX: *GSK SAYS BLENREP COMBINATIONS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA ACCEPTED FOR REGULATORY REVIEW IN JAPAN |
| 16.09 08:08 | dpa-AFX: ANALYSE-FLASH: Goldman belässt GSK auf 'Neutral' - Ziel 1850 Pence |
| 16.09 08:08 | dpa-AFX: Goldman belässt GSK auf 'Neutral' - Ziel 1850 Pence |
| 13.09 11:13 | dpa-AFX: Goldman belässt GSK auf 'Neutral' - Ziel 1850 Pence |
| 13.09 08:15 | dpa-AFX: GSK : Blenrep Combination Receives Breakthrough Therapy Designation For Multiple Myeloma In China |
| 13.09 08:06 | dpa-AFX: *GSK SAYS BLENREP IN COMBINATION RECEIVES BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR TREATMENT OF R/R MULTIPLE MYELOMA |
| 13.09 08:03 | dpa-AFX: *GSK : BLENREP COMBINATION GETS BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR R/R MULTIPLE MYELOMA TREATMENT |
|
|
